Real pricing, honest reviews, and evidence-based guidance for Indian patients navigating Ozempic, Wegovy, and Mounjaro — without the hype.
China is rapidly becoming the most important battleground in the global obesity-drug industry. With hundreds of millions of potential patients, dozens of local competitors, and a wave of innovation, Novo Nordisk and Eli Lilly are fighting for a market that could reshape the future of GLP-1 medicine.
The obesity-drug war has entered a new phase. Oral Wegovy and Foundayo are the first major GLP-1 weight-loss pills competing for millions of patients who prefer tablets over injections. Here's how they compare.
2026 may be remembered as the year obesity treatment entered a new era. Oral GLP-1 pills, generic semaglutide, retatrutide, and next-generation therapies are reshaping one of the fastest-growing healthcare markets in the world.
The era of injectable-only GLP-1 treatment may be coming to an end. With Oral Wegovy now approved in the United States and moving through Europe, the future of obesity treatment could become far more accessible—including in India.
India's generic semaglutide market has triggered one of the biggest pharmaceutical price wars in recent years. With prices already down by as much as 90%, many are asking the same question: how much lower can they go?
Semaglutide · Novo Nordisk
Oral Semaglutide · Novo Nordisk
Tirzepatide · Eli Lilly
Semaglutide 2.4mg · Novo Nordisk